Beijing Anweituo Biomedical

Anweituo Biomedical is a China-based biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary platform to design and optimize molecular glues and PROTACs, focusing on previously undruggable targets in oncology and autoimmune diseases. Founded by industry veterans with expertise in protein structure and medicinal chemistry, Anweituo aims to provide innovative treatment options for patients with high unmet medical needs. The company is currently in the pre-clinical stage, advancing a pipeline of small molecule degraders. It has successfully raised significant venture capital from leading firms like Qiming Venture Partners and IDG Capital to support its research and development efforts.